Synonyms
PDE inhibitors
Definition
There are 11 families of phosphodiesterases (PDEs; PDE1–PDE11), which degrade the second messengers cAMP and/or cGMP. The activity of PDEs can be selectively inhibited with drugs. The most widely known PDE inhibitor is sildenafil, which is one of the three PDE5 inhibitors approved for the treatment of erectile dysfunction and also arterial pulmonary hypertension. In addition, two PDE3 inhibitors are approved for treating congestive heart failure or intermittent claudication, respectively. Recently, one PDE4 inhibitor has been approved for the treatment of chronic obstructive pulmonary disease. At the moment, PDE inhibitors are explored as possible therapeutic CNS drug targets for memory loss (PDE1, PDE2, PDE4, PDE5, PDE9), Alzheimer’s disease (PDE3, PDE4, PDE5, PDE7, PDE9), Parkinson’s disease (PDE1, PDE4, PDE7), Huntington’s disease (PDE1, PDE4, PDE5, PDE10), anxiety (PDE2, PDE5), depression (PDE4), schizophrenia (PDE3, PDE10), pain (PDE4, PDE5), or...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ambriz-Tututi M, Velazquez-Zamora DA, Urquiza-Marin H, Granados-Soto V (2005) Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test. Eur J Pharmacol 512:121–127
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520
Brink CB, Clapton JD, Eagar BE, Harvey BH (2008) Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 115:117–125
Chapman TM, Goa KL (2003) Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 3:117–138
Cheng J, Grande JP (2007) Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med (Maywood) 232:38–51
Esposito K, Reierson GW, Rong Luo H, Sheng Wu G, Licinio J, Wong ML (2009) Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 41:177–185
GarcÃa-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Sallés J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M, GarcÃa-Osta A (2013) Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 64:114–123
Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol 204:167–192
Keravis T, Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signaling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165:1288–1305
Lahu G, Nassr N, Hünnemeyer A (2011) Pharmacokinetic evaluation of roflumilast. Expert Opin 7:1577–1591
Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367–374
Liebenberg N, Harvey BH, Brand L, Wegener G, Brink CB (2012) Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats. Metab Brain Dis 27:337–340
Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670
Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, Pérez-Grijalba V, Krzyzanowska A, Sarasa M, Gil C, Ferrer I, Martinez A, Carro E (2013) Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer’s disease. Neurobiol Aging 34:2133–2145
Puzzo D, Sapienza S, Arancio O, Palmeri A (2008) Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 4:371–387
Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 202:419–443
Sharma S, Kumar K, Deshmukh R, Sharma PL (2013) Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders. Eur J Pharmacol 714:486–497
Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS (2011) Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study. Int J Imp Res 23:109–114
Sierksma AS, Rutten K, Sydlik S, Rostamian S, Steinbusch HW, van den Hove DL, Prickaerts J (2013) Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuropharmacology 64:124–136
Szatmari SZ, Whitehouse PJ (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev(1), CD003119
Xu Y, Zhang HT, O’Donnell JM (2011) Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb Exp Pharmacol 204:447–485
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Prickaerts, J. (2015). Phosphodiesterase Inhibitors. In: Stolerman, I.P., Price, L.H. (eds) Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-36172-2_403
Download citation
DOI: https://doi.org/10.1007/978-3-642-36172-2_403
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-36171-5
Online ISBN: 978-3-642-36172-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences